Calidi Biotherapeutics Inc.
Calidi Biotherapeutics Inc. (CLDI): 5 pipeline candidates · ~5 mo cash runway · 1 clinical trial. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
5.1 months
D/E 0.94 · 0% dilution
Lead: Phase 2
5 candidates
N/A
N/A
A transparent, data-derived signal for Calidi Biotherapeutics Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$3.0M
Cash
$6.8M
Quarterly Burn
$4.1M
Runway
5.1 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (5 candidates)
| Drug | Phase |
|---|---|
| CLD-101 (NeuroNova™) | Phase 2 |
| CLD-201 (SuperNova™ / SNV1) | Phase 1 |
| CLD-301 (AAA) | Preclinical |
| CLD-400 (RTNova) | Preclinical |
| gene therapy | Phase 1/Phase 2 |
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
25
Total value held
$377K
| Holder | Shares | Value |
|---|---|---|
| armistice capital, llc | 879,000 | $210K |
| sabby management, llc | 434,903 | $104K |
| geode capital management, llc | 63,019 | $15K |
| vanguard capital management llc | 51,018 | $12K |
| rs crum inc. | 40,256 | $10K |
| jane street group, llc | 34,802 | $8K |
| belpointe asset management llc | 19,921 | $5K |
| northern trust corp | 17,758 | $4K |
| farther finance advisors, llc | 10,000 | $2K |
| morgan stanley | 9,467 | $2K |
Showing top 10 of 25 institutional holders of Calidi Biotherapeutics Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Calidi Biotherapeutics Inc.'s pipeline?
Calidi Biotherapeutics Inc. (CLDI) has 5 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Calidi Biotherapeutics Inc.'s lead drug candidate?
Calidi Biotherapeutics Inc.'s most advanced tracked candidate is CLD-101 (NeuroNova™) (Phase 2) for High-grade glioma (newly diagnosed and recurrent HGG).
What is Calidi Biotherapeutics Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Calidi Biotherapeutics Inc. has approximately 5.1 months of cash runway.
What is Calidi Biotherapeutics Inc.'s market capitalization?
Calidi Biotherapeutics Inc.'s market capitalization is approximately $3.0M.
Who is the CEO of Calidi Biotherapeutics Inc.?
Dr. Eric E. Poma Ph.D. is the chief executive officer of Calidi Biotherapeutics Inc. (CLDI).
Get the full picture on Calidi Biotherapeutics Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.